Exelixis, Inc. (EXEL) Stock

Exelixis, Inc. (EXEL) is a Healthcare stock trading at $51.92 (as of 2026-06-18), with a market capitalization of $12.59B and a trailing P/E of 16.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Exelixis, Inc. develops and commercializes oncology medicines, including CABOMETYX and COMETRIQ for certain advanced cancers in the United States, along with COTELLIC for advanced melanoma. It also offers MINNEBRO for hypertension in Japan and is developing additional therapies for solid tumors and other cancer types.

Valuation — source: SEC EDGAR (first-party)
Price$51.92
Market Cap$12.59B
P/E Ratio16.6
EV / EBITDA12.8
Price / Book6.50
Price / Sales5.30
DCF Value (model)$86.95
DCF Upside vs Price67.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.32B
Net Margin33.7%
Return on Equity43.1%
Current Ratio3.26
Revenue Growth (YoY)10.0%
EPS Growth (YoY)42.1%
FCF Growth (YoY)20.1%
Financial Health — source: SEC EDGAR
Altman Z-Score14.07 (safe)
Valuation vs Sector & Industry
Stock P/E16.6
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-20.9%
vs Industry-3.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($1.32B)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael Morrissey
Employees1,147
CountryUS
IPO Date2000-04-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Moderna, Inc. (MRNA)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Radiopharm Theranostics Limited (RADX)
  • Elanco Animal Health Incorporated (ELAN)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Qiagen N.V. (QGEN)
EXEL earnings history · EXEL institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.